



Panacea Biotec

Innovation in support of life

17th December, 2012

The Manager, Listing Department
The National Stock Exchange of India Ltd.
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
Fax No.:022-26598237 / 38
NSE Symbol : PANACEABIO

Bombay Stock Exchange Ltd.
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001
Fax No.:022-22721919, 3121
BSE Scrip Code: 531349

Re.: Press Release - Panacea Biotec gets Government of India's Order for Supply of Oral Polio Vaccine worth Rs.187 Crore

Dear Sir,

Pursuant to the provisions of Clause 36 of the Listing Agreement entered with your Exchange, we wish to inform you that the company gets Government of India's orders for supply of 345 million doses of Trivalent Oral Polio Vaccines (tOPV) and Bivalent Oral Polio Vaccine (bOPV) worth Rs.187.61 Crore, to be supplied during the period December 2012 till May 2013 to meet the requirements of National Immunisation Days (NIDs) and Supplementary National Immunisation Days (SNIDs).

A copy of the Press Release being issued to the media, etc. in this regard is enclosed for your kind reference and record please. Kindly acknowledge the receipt.

Thanking you,

Sincerely yours,
for Panacea Biotec Ltd.

Vinod Goel
G.M. Legal & Company Secretary

1. Corporate Relationship Department
The Stock Exchange, Mumbai,
1st Floor, New Trading Ring,
Rotundu Building, P J Towers,
Dalal Street, Fort, Mumbai – 400 001
Fax No.22722037/39/41/61/3121/3719

Panacea Biotec Ltd.

B-1 Extn./ G-3, MCIE, Mathura Road
New Delhi - 110 044, INDIA
Phone: D.I.D. +91-11-4167 9015
PBX: +91-11-4167 9000, Fax: +91-11-4167 9075
Email: vinodgoel@panaceabiotec.com
Website: <http://www.panacea-biotec.com>



Panacea Biotec

Innovation in support of life

Panacea Biotec Gets Government of India's Order for Supply of Oral Polio Vaccine worth Rs. 187 Crore

New Delhi: 17th December 2012: Panacea Biotec, India's 2nd largest producer of vaccines and a highly progressive research based health management company gets Government of India's orders for supply of 345 million doses of Trivalent Oral Polio Vaccines (tOPV) and Bivalent Oral Polio Vaccine (bOPV) worth Rs. 187.61 Crore, to be supplied during the period December 2012 till May 2013 to meet the requirements of National Immunisation Days (NIDs) and Supplementary National Immunisation Days (SNIDs).


As per Govt. of India's orders, Panacea Biotec will supply 125 Million doses of tOPV in the month of December 2012 and 70 Million doses of tOPV in the month of January 2013 for the National Immunisation Days (NIDs). Panacea Biotec will also supply a total of 150 Million doses of bOPV to meet the requirements of Supplementary National Immunisation Days (SNIDs) - 100 Million doses in the month of February 2013 and 50 Million doses in the month of May 2013.

Commenting on the development Dr. Rajesh Jain, Joint Managing Director, Panacea Biotec Ltd. said "We are pleased with this opportunity of supplying OPV vaccines to meet the requirements of NIDs and SNIDs programs. These programs have played a major role in eradication of polio in the country. WHO's Global Polio Eradication Initiative (GPEI) has made great progress based on use of oral poliovirus vaccine (OPV) with a live, attenuated form of Sabin poliovirus strains. India, once known as the world's epicenter of polio, has successfully achieved two years polio-free since its last case, recorded on 13th January 2011. In this gigantic task, Panacea Biotec contributed by producing and supplying more than 9.2 billion doses of OPV over two decades (1990-2011). In fact, Panacea Biotec was the first to develop monovalent types 1 and 3 oral polio vaccines (mOPV1 & mOPV3) and bivalent (1 + 3) oral polio vaccines (bOPV), which have become the most critical weapons in the arsenal of WHO and the Indian Ministry of Health and Family Welfare to prevent the crippling disease. Panacea Biotec has been playing a leadership role in the Vaccine R&D, Manufacturing and Supply to meet demands of National and International agencies for the developing world. Panacea Biotec continues to be committed to polio eradication programme and its objectives as laid down in GPEI & will do all that is needed and is under its control to support the efforts of global community."

About Panacea Biotec:

Recent Past:

Panacea Biotec has signed two important strategic alliances (in the month of September 2012 and in November 2012). Panacea Biotec's alliance with Kremers Urban Pharmaceuticals Inc., a specialty generic drug manufacturer and subsidiary of Belgium-based UCB group and a pioneer





Innovation in support of life

in developing generic versions of pharmaceutical products is for launching 11 High Barrier to Entry Generics in the US market developed by Panacea Biotec. The first product in this portfolio to reach the market was Tacrolimus Capsules, launched in US in November 2012. Panacea Biotec was granted approval of the product from the United States Food and Drug Administration (USFDA) in September 2012.

In the month of September 2012, the company announced a major development by entering into a Strategic Alliance with Osmotica Pharmaceutical Inc., USA, a global pharmaceutical company specializing in drug delivery technologies, for the Research, Development and Commercialization of drug delivery based High Barrier to Entry Generic and Branded Pharmaceuticals for US and key strategic markets across the globe.

Panacea Biotec is one of India's leading research-based health management companies with established research, manufacturing and marketing capabilities. Panacea Biotec is the 2nd largest vaccine producer in India. Panacea Biotec has been ranked as the 3rd largest biotechnology company (ABLE Survey – 2011) and is also amongst the top 40 (ORG IMS TSA MAT March 2011) pharmaceutical companies in India. The company has collaborations and tie-ups with leading national and international research organizations and corporations. The company's state of the art manufacturing facilities for vaccines and pharmaceutical formulations comply with the US-FDA, UK-MHRA, SA-MCC and WHO-cGMP standards. Panacea Biotec has four dedicated research and development centers.

For more information, please contact :-

Mr. P. D. Karan

GM - Business Diversification & Corporate Communication

B-1 Extn. / A-27, Mohan Co-Operative Industrial Estate,

Mathura Road, New Delhi – 110044, INDIA

Tel: + 91 11 41679000 Extn. 1406, 41578080 (Direct)

Fax + 91 11 41578002

Mobile: + 91 9312693040, + 91 9810500539

Email: pdkaran@panaceabiotec.com

Web: www.panaceabiotec.com

